Yoshiaki Shoji

Dr. Yoshiaki Shoji

Department of Gastroenterological Surgery, Tokai University School of Medicine, Isehara, Kanagawa, Japan
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2019 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
YSYoshiaki Shoji
Yoshiaki Shoji
SNSouya Nunobe
Souya Nunobe
SISatoshi Ida
Satoshi Ida
KKKoshi Kumagai
Koshi Kumagai
MOManabu Ohashi
Manabu Ohashi
NHNaoki Hiki
Naoki Hiki

21 May 2024 in World Journal of Gastroenterology
Verified
Journal Article
Open access
YSYoshiaki Shoji
Yoshiaki Shoji
KKKAZUO KOYANAGI
KAZUO KOYANAGI
KKKohei Kanamori
Kohei Kanamori
KTKohei Tajima
Kohei Tajima
MOMika Ogimi
Mika Ogimi
MMMasaki Mori
Masaki Mori
Immune checkpoint inhibitor therapy has dramatically improved patient prognosis, and thereby transformed the treatment in various cancer types including esophageal squamous cell carcinoma (ESCC) in the past decade. Monoclonal antibodies that selectively inhibit programmed cell death-1 (PD-1) activity has now become standard of care in the treatment of ESCC in metastatic settings, and has a high expectation to provide clinical benefit during perioperative period. Further, anti-cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) monoclonal antibody has also been approved in the treatment of recurrent/metastatic ESCC in combination with anti-PD-1 antibody. Well understanding of the existing evidence of immune-based treatments for ESCC, as well as recent clinical trials on various combinations with chemotherapy for different clinical settings including neoadjuvant, adjuvant, and metastatic diseases, may provide future prospects of ESCC treatment for better patient outcomes.

29 November 2017 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
KEKojiro Eto
Kojiro Eto
NHNaoki Hiki
Naoki Hiki
KKKoshi Kumagai
Koshi Kumagai
YSYoshiaki Shoji
Yoshiaki Shoji
YTYasuo Tsuda
Yasuo Tsuda
TYToshiharu Yamaguchi
Toshiharu Yamaguchi

3 January 2019 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
YSYoshiaki Shoji
Yoshiaki Shoji
KKKoshi Kumagai
Koshi Kumagai
SKSatoshi Kamiya
Satoshi Kamiya
SISatoshi Ida
Satoshi Ida
SNSouya Nunobe
Souya Nunobe
NHNaoki Hiki
Naoki Hiki

25 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MBMATIAS ALBERTO BUSTOS
MATIAS ALBERTO BUSTOS
KTKevin D. Tran
Kevin D. Tran
NRNegin Rahimzadeh
Negin Rahimzadeh
RGRebecca Gross
Rebecca Gross
SLSelena Lin
Selena Lin
DHDave Hoon
Dave Hoon
Primary cutaneous melanoma frequently metastasizes to distant organs including the brain. Identification of cell-free microRNAs (cfmiRs) found in the blood can be used as potential body fluid biomarkers for detecting and monitoring patients with melanoma brain metastasis (MBM). In this pilot study, we initially aimed to identify cfmiRs in the blood of MBM patients. Normal donors plasma (healthy, n = 48) and pre-operative MBM patients’ plasma samples (n = 36) were compared for differences in >2000 microRNAs (miRs) using a next generation sequencing (NGS) probe-based assay. A 74 cfmiR signature was identified in an initial cohort of MBM plasma samples and then verified in a second cohort of MBM plasma samples (n = 24). Of these, only 58 cfmiRs were also detected in MBM tissues (n = 24). CfmiR signatures were also found in patients who have lung and breast cancer brain metastasis (n = 13) and glioblastomas (n = 36) compared to MBM plasma samples. The 74 cfmiR signature and the latter cfmiR signatures were then compared. We found a 6 cfmiR signature that was commonly upregulated in MBM plasma samples in all of the comparisons, and a 29 cfmiR signature that distinguishes MBM patients from normal donors’ samples. In addition, we assessed for cfmiRs in plasma (n = 20) and urine (n = 14) samples collected from metastatic melanoma patients receiving checkpoint inhibitor immunotherapy (CII). Pre- and post-treatment samples showed consistent changes in cfmiRs. Analysis of pre- and post-treatment plasma samples showed 8 differentially expressed (DE) cfmiRs that overlapped with the 35 cfmiR signature found in MBM patients. In paired pre-treatment plasma and urine samples receiving CII 8 cfmiRs overlapped. This study identified specific cfmiRs in MBM plasma samples that may potentially allow for assessment of melanoma patients developing MBM. The cfmiR signatures identified in both blood and urine may have potential utility to assess CII responses after further validation.

20 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
THTadashi Higuchi
Tadashi Higuchi
YSYoshiaki Shoji
Yoshiaki Shoji
KKKAZUO KOYANAGI
KAZUO KOYANAGI
KTKohei Tajima
Kohei Tajima
KKKohei Kanamori
Kohei Kanamori
KNKenji Nakamura
Kenji Nakamura
Esophageal cancer is the seventh most common malignancy and sixth most common cause of cancer-related death globally. Esophageal squamous cell carcinoma (ESCC) with aortic or tracheal invasion is considered unresectable, and has an extremely poor prognosis; its standard treatment is definitive chemoradiotherapy (dCRT). In recent years, induction chemotherapy (ICT) has been reported to yield high response rates for locally advanced ESCC, and the efficacy and safety of ICT followed by conversion surgery (CS) have been investigated. Multimodal treatment, combining surgery with induction chemoradiotherapy (ICRT) or ICT, is necessary to improve ESCC prognosis. CS is generally performed for locally advanced ECC after ICRT or ICT when tumor downstaging is achieved, although its prognostic benefit remains controversial. The Japan Clinical Oncology Group (JCOG) has conducted a three-arm phase III randomized controlled trial (JCOG1510) to confirm the superiority of DCF (docetaxel, cisplatin, and 5-fluorouracil) ICT, over conventional dCRT, among patients with initially unresectable ESCC. In recent years, researchers have reported favorable outcomes of induction therapy followed by CS and salvage surgery, after dCRT or systemic immunochemotherapy. In this review, we will describe the latest developments in the multimodal treatment including chemotherapy, CRT, surgery, and immunotherapy, which may improve oncological and survival outcomes for patients with cT4 ESCC.